ArticleArthritis research & therapy2024
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study.
Abstract readMulticenter Study
In one paragraph
Article in Arthritis research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic value of antiphospholipid antibodies in pregnancy outcomes in systemic lupus erythematosus.RMD open · 2026Article
- Mapping organ-associated autoantigenic landscapes in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.Clinical rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Jun Li *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Liying Peng *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Lijun Wu *Department of Rheumatology and Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China.
Yufang DingDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Xinwang DuanDepartment of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Jian XuDepartment of Rheumatology and Immunology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Wei WeiDepartment of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Zhen ChenDepartment of Rheumatology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Cheng ZhaoDepartment of Rheumatology and Immunology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, China.
Min YangDepartment of Rheumatic & TCM Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Nan JiangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Shangzhu ZhangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Qian WangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Xinping TianDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Mengtao LiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China.
Xiaofeng ZengDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China. zengxfpumc@163.com.
Yan ZhaoDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China. zhaoyan_pumch2002@aliyun.com.
Jiuliang ZhaoDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Ministry of Education, Beijing, 100730, China. zjlpumc@sina.com.
Funding
Beijing Municipal Science & Technology Commission No. Z201100005520022,23, 25-27CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-005Chinese National Key Technology R&D Program, Ministry of Science and Technology 2021YFC2501300National High Level Hospital Clinical Research Funding 2022-PUMCH-D-009
Abstract
backgroundTo investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP).
methodsThis multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count<100 × 10
resultsA total of 350 SLE-TP patients with complete follow-up data, 194 (55.4%) were aPLs positive. At baseline, SLE-TP patients with aPLs had lower baseline platelet counts (61.0 × 10
conclusionSLE-TP patients with positive aPLs had more severe disease a lower remission rate but a higher relapse rate.
Indexed as
Antiphospholipid SyndromeLupus Erythematosus, SystemicThrombocytopeniaAntibodies, AntiphospholipidCohort StudiesHumansPatient AcuityPrognosisProspective StudiesRecurrenceAntibodies, AntiphospholipidAntiphospholipid antibodiesPrognosisSeveritySystemic Lupus ErythematosusThrombocytopenia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.